Skip to search formSkip to main contentSkip to account menu

EGFR T790M Inhibitor PF-06747775

Known as: PF-06747775 
An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. EGFR T790M… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Mutaciones del gen del receptor del factor de crecimiento epidérmico (egfr) en pacientes con carcinoma no microcítico de pulmón: cribado poblacional, significado predictivo y pronóstico y estrategias…
Resumen: La presente tesis doctoral se basa en la compilacion de dos articulos que versan sobre el estudio de los pacientes con… 
Review
2019
Review
2019
Prior EGFR ‐ TKI Treatment in EGFR ‐ Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T 790 M and the Subsequent Efficacy of
Background The first (1G) and second (2G) generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs… 
2016
2016
非小細胞肺癌における新規EGFR チロシンキナーゼ不可逆的阻害剤Osimertinib−基礎と臨床−
Osimertinib is an oral, potent, irreversible EGFR tyrosine kinase inhibitor that is selective for EGFR tyrosine kinase inhibitor… 
2015
2015
Correction: Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
2015
2015
The role of EGFR TKIs in different settings The Iressa
Introduction: Lung cancer is the leading cause of cancer-related death worldwide. It is usually diagnosed at advanced stage for… 
2015
2015
GFR mutation detection in ctDNA from NSCLC patient plasma : A ross-platform comparison of leading technologies to support the linical development of AZD 9291 enneth
Objectives: To assess the ability of different technology platforms to detect epidermal growth factor receptor (EGFR) mutations… 
2015
2015
Lung cancer: A sanguine approach
Blood-based identification of resistance mechanisms can noninvasively select patients for treatment with third-generation EGFR… 
2014
2014
Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.
EGFR mutant lung cancers are highly sensitive to first generation EGFR tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib… 
2014
2014
Abstract LB-232: Potent, novel small molecule inhibitors targeting EGFR L858R/T790M mutation for non-small cell lung cancer
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: EGFR targeted therapies like Tarceva are…